Piramal Healthcare on Monday announced that it has bought world-wide rights for potential Alzheimer’s tracers developed by molecular-imaging and development. However, the deal amount was not disclosed.

Piramal Helathcare

In the statement, Piramal mentioned that the company is shifting from making branded generic medicines to making exclusive patent protected products indicating their change in approach with regards to pharmaceutical business.

Bayer

Florbetaben was the most important of all which is in the final stages of clinical trials, then goes for the regulatory approval. Piramal is also planning to file for approval in US in third quarter, later this year where about 25 million people are expected to suffer from the disease in 2023 and the number is expected to touch 100 million by 2050.

This acquisition might also bring other tracers related to cancer, heart and nervous-system which are in early stages for now. Also, a team of 20 scientists will move from Bayer to Piramal.